Gilead tags Merck for first-line triple negative breast cancer trial
pharmaphorum
OCTOBER 29, 2021
Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. Analysts welcomed the performance but also noted it points to underlying weakness at the company.
Let's personalize your content